Ultragenyx Pharma (RARE) Misses Q1 EPS by 38c, provides guidance

Ultragenyx Pharma (NASDAQ: RARE) reported Q1 EPS of ($1.84), $0.38 worse than the analyst estimate of ($1.46). Revenue for the quarter came in at $136 million versus the consensus estimate of $160.69 million.

GUIDANCE:

Ultragenyx Pharma sees FY2026 revenue of $730-760 million, versus the consensus of $746.2 million.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• RH (RH) Tops Q1 EPS by 12c
• 51Talk Online Education Group (COE) Reports Q1 EPS of $0.00